Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit
暂无分享,去创建一个
F. Sadeghipour | P. Eggimann | Y. Que | J. Pagani | A. Fournier | A. Pannatier | A. Fournier | P. Eggimann | O. Pantet | J. L. Pagani | E. Dupuis-Lozeron | A. Pannatier | F. Sadeghipour | P. Voirol | Y.-A. Que | E. Dupuis-Lozeron | P. Voirol | O. Pantet
[1] Gabrielle Wilcox. Infection prevention and treatment in patients with major burn injuries , 2010 .
[2] M. Ansermino,et al. Intensive care management and control of infection , 2004, BMJ : British Medical Journal.
[3] J. Revelly,et al. Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections. , 2016, Burns : journal of the International Society for Burn Injuries.
[4] L. Decosterd,et al. Prospective Determination of Plasma Imipenem Concentrations in Critically Ill Children , 2006, Antimicrobial Agents and Chemotherapy.
[5] F. Taccone,et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients , 2016, Expert review of clinical pharmacology.
[6] J. Rello,et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. , 2010, The Journal of antimicrobial chemotherapy.
[7] D. Bacquer,et al. Development and validation of a model for prediction of mortality in patients with acute burn injury , 2009, The British journal of surgery.
[8] P. Dziewulski,et al. Cause of death and correlation with autopsy findings in burns patients. , 2013, Burns : journal of the International Society for Burn Injuries.
[9] D. Nicolau,et al. Pharmacokinetics of Doripenem in Infected Patients Treated Within and Outside the Intensive Care Unit , 2013, The Annals of pharmacotherapy.
[10] E. Alp,et al. Risk Factors for Nosocomial Infection and Mortality in Burn Patients: 10 Years of Experience at a University Hospital , 2012, Journal of burn care & research : official publication of the American Burn Association.
[11] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Revelly,et al. Staphylococcus aureus carriage at admission predicts early-onset pneumonia after burn trauma , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[13] A. Shorr,et al. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients , 2013, Critical Care.
[14] A. Boyer,et al. Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment , 2011, Critical care.
[15] Ronald N. Jones,et al. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[17] M. Lesseva. Central venous catheter-related bacteraemia in burn patients. , 1998, Scandinavian journal of infectious diseases.
[18] R. Boots,et al. ARC--augmented renal clearance. , 2011, Current pharmaceutical biotechnology.
[19] R. Salisbury. Development and validation of a model for prediction of mortality in patients with acute burn injury , 2010 .
[20] S. Harbarth,et al. Therapeutic drug monitoring of the β-lactam antibiotics: what is the evidence and which patients should we be using it for? , 2015, The Journal of antimicrobial chemotherapy.
[21] M. Roberts,et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. , 2014, The Journal of antimicrobial chemotherapy.
[22] Alexander A. Morgan,et al. Prediction of Multiple Infections After Severe Burn Trauma , 2015 .
[23] R. Gamelli,et al. Ten year experience of burn, trauma, and combined burn/trauma injuries comparing outcomes. , 2004, The Journal of trauma.
[24] R. Gamelli,et al. Morbidity and Survival Probability in Burn Patients in Modern Burn Care* , 2015, Critical care medicine.
[25] J. Roberts,et al. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. , 2013, International journal of antimicrobial agents.
[26] J. Rello,et al. The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients , 2011, Clinical pharmacokinetics.
[27] D. Paterson,et al. Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study , 2012, Therapeutic drug monitoring.
[28] D. Smith,et al. Effect of inhalation injury, burn size, and age on mortality: a study of 1447 consecutive burn patients. , 1994, The Journal of trauma.
[29] A. Šimek,et al. Antimicrobial agents , 2008, Folia Microbiologica.
[30] V. Briedis,et al. Augmented renal clearance – an evolving risk factor to consider during the treatment with vancomycin , 2013, Journal of clinical pharmacy and therapeutics.
[31] M. Kollef,et al. Antibiotic stewardship in the intensive care unit. , 2011, Seminars in respiratory and critical care medicine.
[32] M. Berger,et al. Standardizing the diagnosis of inhalation injury using a descriptive score based on mucosal injury criteria. , 2012, Burns : journal of the International Society for Burn Injuries.
[33] L. Decosterd,et al. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. , 2015, Burns : journal of the International Society for Burn Injuries.
[34] K. Colpaert,et al. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. , 2013, Journal of critical care.
[35] D. Church,et al. Burn Wound Infections , 2006, Clinical Microbiology Reviews.
[36] G. Rowley-Conwy,et al. Infection prevention and treatment in patients with major burn injuries. , 2010, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[37] J. Minei,et al. Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core--standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. , 2006, The Journal of trauma.
[38] M. Berger,et al. Prospective monitoring of cefepime in intensive care unit adult patients , 2011 .
[39] K. Colpaert,et al. Outcome and changes over time in survival following severe burns from 1985 to 2004 , 2005, Intensive Care Medicine.
[40] C. Ryan,et al. Objective estimates of the probability of death from burn injuries. , 1998, The New England journal of medicine.
[41] U. Tröger,et al. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. , 2013, International journal of antimicrobial agents.
[42] A. Telenti,et al. 14. Antimicrobial Agents , 2012 .
[43] J. Roberts,et al. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? , 2014, BMC Infectious Diseases.